Influenza Vaccines Market – By Vaccine Type (Inactivated, Live Attenuated), Indication (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Flu Type (Seasonal, Pandemic), Age Group, Route of Administration, End-user, Global Forecast 2024 – 2032

Influenza Vaccines Market – By Vaccine Type (Inactivated, Live Attenuated), Indication (Quadrivalent, Trivalent), Technology (Egg-based, Cell-based), Flu Type (Seasonal, Pandemic), Age Group, Route of Administration, End-user, Global Forecast 2024 – 2032

Influenza vaccine market is expected to witness 6.8% CAGR between 2024 and 2032, driven by increasing prevalence of influenza viruses worldwide. As per WHO, annually, approximately 1 billion cases of seasonal influenza occur, with 3–5 million cases classified as severe illnesses. The rising awareness about the importance of vaccination in preventing the spread of influenza and its associated complications among healthcare professionals and the population is further boosting the demand for influenza vaccines. Moreover, government initiatives aimed at promoting vaccination campaigns and associated with the expansion of immunization programs in both developed and developing countries will contribute to the product uptake.

Rising advancements in vaccine technology, such as the development of more effective and safer formulations will stimulate the market growth for enhancing vaccine efficacy and safety. Strategic collaborations among vaccine manufacturers and research institutions is driving the development of novel influenza vaccine candidates. Moreover, the growing geriatric population and increasing healthcare expenditure globally will further fuel the product demand.

The influenza vaccine industry is divided into vaccine type, indication, technology, flu type, age group, route of administration, end-user, and region

The market share from the cell- based technology segment will record a 5% growth rate through 2032, as advancements in vaccine manufacturing technology have enabled the production of influenza vaccines. Cell-based vaccines are less susceptible to issues related to egg supply variability and can be rapidly scaled up to meet the rising demand during influenza outbreaks. Additionally, the growing concerns regarding egg allergies and the need for alternative vaccine production methods will further drive the segment growth.

With respect to route of administration, the influenza vaccine market from the nasal spray segment is slated to generate notable gains at 5.9% CAGR from 2024 to 2032, backed by the non-invasive alternatives to traditional injectable vaccines. Nasal spray vaccines stimulate a mucosal immune response in the respiratory tract for potentially providing broader protection against influenza viruses. Furthermore, the convenience and ease of administration makes them particularly suitable for large-scale vaccination campaigns and community immunization programs, thereby expanding the vaccine coverage.

Europe influenza vaccines industry size will witness 7% CAGR through 2032, due to rising burden of seasonal influenza outbreaks. Robust immunization programs and high vaccination coverage rates in many European countries are contributing to the sustained product demand. Stringent regulatory standards and surveillance systems to ensure the safety and efficacy of influenza vaccines are instilling confidence among healthcare professionals and the general population. Furthermore, the presence of leading vaccine manufacturers and the ongoing research will contribute to the regional industry expansion.